 |
인쇄하기
취소
|
Daewoong announces partnership with Supernus Pharmaceuticals
Daewoong Pharm says it has signed an exclusive agreement with the US based Supernus Pharmaceuticals Inc. to distribute a controlled-release Epliga in Korea, possibly in 2012.
Epliga, an epilepsy medicine, is a novel once-per-day dosage form of oxcarbazepine that is designed to improve compliance and reduce adverse events.
"We are excited about Epliga and its potential for offering epileps...
Epliga, an epilepsy medicine, is a novel once-per-day dosage form of oxcarbazepine that is designed to improve compliance and reduce adverse events.
"We are excited about Epliga and its potential for offering epileps...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.